Phase II clinical trial: Safety and efficacy study of tocilizumab (Toci) in combination with ipilimumab (Ipi) 3mg/kg plus nivolumab (Nivo) 1mg/kg in patients (pts) with metastatic melanoma (MM) Article
Full Text via DOI: 10.1016/j.annonc.2022.07.948
Web of Science: 000866211601093